Detection Of Circulating Tumor Cells (Liquid Biopsies) Using Merisistm Ctc Kit
*Corresponding Author:
Copyright: © 2020 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Objective: Circulating tumor cells (CTC) has prognostic value in patients with solid tumors, such as advanced breast, colon, and prostate cancer. The main diagnostic and treatment methods for patients with cancer are gradually shifting from conventional standards to personalized techniques. At Diponed BioIntelligence, we developed a CTC isolation kit integrated with a miniaturized filter for CTC isolation.
Methods: Paired peripheral blood samples were collected from 20 cancer patients (10 suspects and 10 confirmed cases of cancer) to enumerate CTCs using MerisisTM CTC Kit. The results are compared with healthy controls.
Results: The number CTCs detected were ≥ 10/10ml of blood in Confirmed cancer cases using MerisisTM CTC Kit. The numbers of CTC’s were ≤ 5 in healthy and suspected cancer patients.
Conclusions: The MerisisTM CTC Kit has a potential to isolate significantly more CTCs and CTC clusters in advanced stage cancer patients.
